Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Pfizer Inc. is conducting a study titled ‘Real-world Effectiveness of the 20-valent Pneumococcal Conjugate Vaccine (PCV20) Among Medicare Fee-for-service Beneficiaries Aged ≥65 Years in the United States.’ The study aims to evaluate how well the Prevnar 20 vaccine prevents various types of pneumonia and lower respiratory tract infections in people aged 65 and older. This research is significant as it seeks to confirm the vaccine’s effectiveness in a real-world setting, potentially influencing future vaccination recommendations for older adults.
The intervention being tested is the Prevnar 20 vaccine, a 20-valent pneumococcal conjugate vaccine designed to prevent invasive pneumococcal disease, pneumococcal pneumonia, and other related infections. The vaccine includes additional serotypes beyond those covered by previous vaccines, aiming to provide broader protection.
This study is observational and retrospective, using existing Medicare data to assess vaccine effectiveness. Participants are divided into two groups: those vaccinated with PCV20 and those who are not. The primary purpose is to estimate the vaccine’s overall effectiveness against specific infections in the elderly population.
The study began on January 20, 2025, and its primary completion is yet to be determined. The latest update was submitted on June 26, 2025. These dates are crucial as they indicate the study’s progress and the timeline for potential results.
The study’s findings could have significant market implications for Pfizer, potentially boosting its stock performance if the vaccine is shown to be highly effective. This could also impact investor sentiment positively, especially in the context of competitive vaccines like PCV15 and PPSV23. The outcome may influence the broader vaccine market, particularly in the elderly demographic.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.